Literature DB >> 29189256

Enteric Pathologic Manifestations of Alpha-Synucleinopathies.

Michael Punsoni1, Joseph H Friedman2, Murray Resnick1, John E Donahue1, Dong Fang Yang1, Edward G Stopa1.   

Abstract

BACKGROUND: Gastrointestinal (GI) symptoms are common in Parkinson disease (PD), often preceding neurological manifestations; however, early diagnostic utility of GI biopsies remains controversial. Studies suggest aberrant deposition of alpha-synuclein (α-syn) follows step-wise progression in central nervous system though histologic interpretation of normal and aberrant staining patterns have shown variable results. This study examines whether GI α-syn mRNA expression combined with standard α-syn immunohistochemical staining enhance the role of GI biopsy in PD.
MATERIALS AND METHODS: Four groups were examined, including pediatric (21) and adult control patients (18), PD clinic patients (17), and pathologically confirmed PD cases from hospital archives (16). Enteric nervous system α-syn staining was evaluated by immunohistochemistry in 33 PD and 39 controls. α-Syn mRNA levels were compared between patient groups using quantitative polymerase chain reaction and stomach and colon levels in PD.
RESULTS: PD patients had Lewy bodies (LB) and diffuse neuronal α-syn staining. GI tissues from elderly controls, children, and young adults exhibited diffuse positivity. LB were limited to PD. Myenteric plexus immunoreactivity varied in different regions. Widespread staining was noted within stomach and colon. Immunoreactivity was present within esophagus, appendix, and small bowel. α-Syn mRNA expression was highest in PD; however, levels varied between proximal and distal GI tract.
CONCLUSIONS: α-Syn is normally present within young and elderly enteric nervous system; furthermore, while α-syn mRNA is always detectable, levels are highest and most variable in PD. This suggests that enteric α-syn may be altered in neurodegenerative disease. The presence of LB in the GI tract, not solely α-syn expression, may prove useful, distinguishing neurodegenerative disease patients from normal controls.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29189256     DOI: 10.1097/PAI.0000000000000613

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

Review 1.  Review: The Role of Intestinal Dysbiosis in Parkinson's Disease.

Authors:  Yiying Huang; Jinchi Liao; Xu Liu; Yunxiao Zhong; Xiaodong Cai; Ling Long
Journal:  Front Cell Infect Microbiol       Date:  2021-04-22       Impact factor: 5.293

Review 2.  Microbiota in Health and Disease-Potential Clinical Applications.

Authors:  Matthias Laudes; Corinna Geisler; Nathalie Rohmann; Jildau Bouwman; Tobias Pischon; Kristina Schlicht
Journal:  Nutrients       Date:  2021-10-29       Impact factor: 5.717

Review 3.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis.

Authors:  Laura M Butkovich; Madelyn C Houser; Malú G Tansey
Journal:  Front Neurosci       Date:  2018-09-11       Impact factor: 4.677

Review 4.  Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease.

Authors:  David J McGee; Xiao-Hong Lu; Elizabeth A Disbrow
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.